Accelerated superfractionated radiotherapy with concomitant boost for invasive bladder cancer

Area of Science:

• Oncology
• Radiation Oncology
• Urologic Oncology

Background:

• Locally invasive bladder cancer presents a significant treatment challenge, often requiring complex therapeutic strategies.
• Conventional radiotherapy approaches may have limitations in achieving optimal local control and survival outcomes.
• Accelerated fractionation techniques are being explored to improve treatment efficacy.

Purpose of the Study:

• To evaluate the toxicity and clinical effectiveness of accelerated superfractionated radiotherapy with delayed concomitant boost (ASCBRT).
• To assess ASCBRT in patients with locally invasive bladder cancer who are unsuitable for or refuse cystectomy.
• To determine local control, distant disease control, and survival rates following ASCBRT.

Main Methods:

• Eighty-seven patients with invasive bladder cancer received ASCBRT between 1997 and 2001.
• The treatment involved conventional daily fractions to the whole pelvis followed by a small field boost during the last 3 weeks.
• Patients were monitored for toxicity, local control, and survival outcomes.

Main Results:

• ASCBRT was completed by most patients with acceptable acute and late toxicity profiles.
• Three-year actuarial rates included 64% local control, 78% distant disease control, 58% cause-specific survival, and 46% overall survival.
• T stage was an independent predictor of complete response, with higher local control rates for T2 compared to T3 stages.

Conclusions:

• ASCBRT is a feasible radiotherapy option with acceptable tolerance in elderly patients with locally invasive bladder cancer (Stage T3 or greater).
• The observed locoregional control and survival results are encouraging and compare favorably to other radiotherapy series.
• ASCBRT merits further investigation in a Phase III clinical trial to confirm its efficacy and role in bladder cancer treatment.